BiotechTube

Capivasertib + Itraconazole

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Conditions

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Trial Timeline

Feb 1, 2021 → Mar 25, 2021

NCT ID
NCT04712396

About Capivasertib + Itraconazole

Capivasertib + Itraconazole is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer). The current trial status is completed. This product is registered under clinical trial identifier NCT04712396. Target conditions include Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer).

What happened to similar drugs?

20 of 20 similar drugs in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) were approved

Approved (20) Terminated (1) Active (0)
✅mRNA-1273.712ModernaApproved
✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved
✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved
✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved
✅Perampanel 6 MGEisaiApproved
✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved
✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04712396Phase 1Completed

Competing Products

20 competing products in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-6231ModernaPhase 1
0
LetrozoleDr. Reddy's LaboratoriesPhase 1
26
IsotretinoinDr. Reddy's LaboratoriesPhase 1
26
FexofenadineDr. Reddy's LaboratoriesPhase 1
26
SertralineDr. Reddy's LaboratoriesPhase 1
26
Nizatidine + AxidDr. Reddy's LaboratoriesPhase 1
26
AnastrozoleDr. Reddy's LaboratoriesPhase 1
26
mRNA-1273.712ModernaApproved
0
RisperidoneDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
Metformin + GlucophageDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
mRNA-0184ModernaPhase 1
0
Divalproex SodiumDr. Reddy's LaboratoriesPhase 1
26
SirolimusDr. Reddy's LaboratoriesPhase 1
26
GlimepirideDr. Reddy's LaboratoriesPhase 1
26
Ziprasidone HydrochlorideDr. Reddy's LaboratoriesPhase 1
26
Naproxen sodiumDr. Reddy's LaboratoriesPhase 1
26